Discover our regulatory-compliant API catalog, key intermediates, and custom peptide solutions available for bulk global distribution.
An authoritative industrial guide on Axitinib synthesis, polymorph stability control, and regulatory compliance for global oncology drug manufacturers.
Axitinib (CAS No. 319460-85-0) is an indazole-derived, selective small-molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3 with sub-nanomolar potency ($IC_{50}$ values of 0.1 nM, 0.2 nM, and 0.1 nM, respectively). Recognized globally as a pivotal therapeutic agent for advanced renal cell carcinoma (RCC), securing a resilient, high-purity supply chain of Axitinib Active Pharmaceutical Ingredient (API) is critical for secondary pharmaceutical formulators, dosage manufacturers, and clinical development institutions.
As a trustworthy Wholesale Axitinib Exporter, our manufacturing protocols prioritize strictly controlled crystallization kinetics, minimizing polymorphic transition risks while maintaining sub-ppm impurity thresholds. Below is the structural and analytical specification matrix for commercial procurement:
| Parameter | Analytical Specification | Testing Methodology |
|---|---|---|
| Chemical Name | N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide | IUPAC Nomenclature |
| Molecular Formula | C22H18N4OS | Mass Spectrometry (HRMS) |
| Molecular Weight | 386.47 g/mol | Calculated Monoisotopic Mass |
| Appearance | White to Off-White Crystalline Powder | Visual Inspection |
| Assay (Purity) | 99.5% - 100.5% (Dried Basis) | HPLC (RP-Phase, UV at 320 nm) |
| Polymorphic Identity | Polymorph Form IV / Form X (Customizable) | X-Ray Powder Diffraction (XRPD) / DSC |
| Single Specified Impurity | ≤ 0.10% | High-Performance Liquid Chromatography |
| Residual Solvents | Meets ICH Q3C Guidelines (Methanol, DMF, DCM < limits) | Headspace GC-FID |
| Heavy Metals / Elemental | Meets ICH Q3D requirements (< 10 ppm) | ICP-MS |
Advancements in process chemistry, green continuous-flow synthesis, and crystalline state engineering.
Traditional batch manufacturing of indazole derivatives encounters thermal runaway risks during the diazotization and Heck coupling steps. Our advanced synthesis platform utilizes continuous micro-reactor flow systems, achieving real-time stoichiometry control, reduced reaction dwell times, and 98% direct yield optimization.
Axitinib exhibits extensive polymorphism (over 5 distinct anhydrous forms and solvates). Form IV is favored for pharmaceutical dosage forms due to thermodynamic stability. Our anti-solvent crystallization processes guarantee strict polymorphic phase purity with tailored Particle Size Distribution (PSD $D_{90} < 10\mu m$) for enhanced dissolution kinetics.
Aligning with stringent FDA and EMA regulatory mandates, our quality assurance protocols incorporate ultra-sensitive LC-MS/MS testing for potential N-nitrosamine precursors. Genotoxic organic impurities are kept strictly below 1.5 $\mu$g/day Threshold of Toxicological Concern (TTC).
Navigating combination therapies, generic market access, and global supply stability for active pharmaceutical ingredients.
The global oncology market is experiencing a structural paradigm shift toward combination immuno-oncology regimes. Axitinib has emerged as a cornerstone partner molecule when co-administered with immune checkpoint inhibitors (such as anti-PD-1/PD-L1 monoclonal antibodies). This clinical synergy has dramatically heightened the international demand for reliable, large-scale Wholesale Axitinib suppliers who can guarantee uninterrupted volume expansion and multi-regional regulatory documentation.
As clinical indications broaden to include thyroid cancer, melanoma trials, and solid tumor combinations, our manufacturing facilities provide scalable supply contracts from kilogram pilot scale to metric-ton commercial capacity, reducing lead times by up to 40%.
With key patent expirations in major territories, regional drug developers require fast-track access to Drug Master Files (DMF) and Certificates of Suitability (CEP). We supply comprehensive CTD-format Module 3 regulatory dossiers to accelerate generic filing approvals.
To address Axitinib's Class II BCS classification (low solubility, high permeability), our technical team offers specialized micronization, co-precipitation, and solid dispersion grade APIs tailored to optimized oral bioavailable final dosage forms.
Leveraging smart manufacturing, vertical integration, and standard-setting quality assurance for global chemical supply.
Gentolex operates at the forefront of China's pharmaceutical manufacturing evolution. By integrating automated batch execution systems (BES), real-time process analytical technology (PAT), and centralized digital supply networks, we offer unprecedented lot-to-lot consistency and structural cost-efficiencies.
Our state-of-the-art facility encompasses 250,000 square meters designed under stringent international cGMP and ISO standards. We accommodate specialized high-containment suites (OEB-4/5) specifically for potent oncology compounds like Axitinib.
Supply stability begins with core building blocks. By synthesizing 6-substituted indazole key intermediates in-house, we remove vulnerabilities associated with third-party chemical bottlenecks, guaranteeing stable delivery schedules regardless of global geopolitical shifts.
Equipped with advanced catalytic oxidation, zero-liquid-discharge (ZLD) effluent treatment systems, and hazardous waste reclamation units, our operations guarantee long-term environmental sustainability and uninterrupted production authorization.
Connecting global health networks through certified pharmaceutical ingredients, peptide engineering, and streamlined procurement.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Comprehensive technical support, lab setup, custom peptide synthesis, and novel delivery system engineering from lab-bench to commercial scale.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Dedicated trade representation in North America, Latin America, Europe, and Africa to streamline clearance and compliance.
We provide fully compiled US DMF, EU CEP/COS documentation, open/closed parts of Drug Master Files, stability studies under ICH Q1A(R2) conditions (accelerated and long-term), and certified CoA per batch shipment.
Axitinib API powder requires protection from moisture, light, and thermal exposure. Our export-grade packaging uses double polyethylene liners, sealed vacuum aluminum bags, and UN-certified fiber drums with temperature monitoring sensors during transit.
With specialized trade entities established in Mexico and South Africa, Gentolex offers localized client consultation, currency flexibility, real-time customs support, and regional warehouse dispatch across Latin America and EMEA regions.
Stay updated with the latest breakthroughs in peptide technology, API manufacturing, and life science research.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Developed through neuropharmacological research, Selank is a derivative of endogenous peptide...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and academic institutions worldwide...
View Details
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation...
View Details
With continuous developments in neuroscience and peptide technology, Semax, a synthetic peptide derived from an ACTH fragment, has attracted significant attention due to its unique molecular biological interactions and stability profiles...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial bioenergetics...
View DetailsDetailed answers to critical procurement, quality control, and technical synthesis queries regarding wholesale Axitinib API.
Explore further chemical components, specialty plasticizers, and high-purity peptides available for direct supply.
